Introduction: Disulfidptosis is a recently identified form of non-apoptotic programmed cell death which distinguishes itself from classical cell death pathways. However, the prognostic implications of disulfidptosis-related long non-coding RNAs (DRLs) and their underlying mechanisms in hepatocellular carcinoma (HCC) remain largely unexplored.Methods: In this study, we leveraged RNA-sequencing data and clinical information of HCC patients from the TCGA database. Through expression correlation and prognostic correlation analyses, we identified a set of top-performing long non-coding RNAs. Subsequently, a 5-DRLs predictive signature was established by conducting a Lasso regression analysis.Results: This signature effectively stratified patients into high- and low-risk groups, revealing notable differences in survival outcomes. Further validation through univariate and multivariate Cox regression analyses confirmed that the risk score derived from our signature independently predicted the prognosis of HCC patients. Moreover, we observed significant disparities in immune cell infiltration and tumor mutation burden (TMB) between the two risk groups, shedding light on the potential connection between immune-related mechanisms and disulfidptosis. Notably, the signature also exhibited predictive value in the context of chemotherapeutic drug sensitivity and immunotherapy efficacy for HCC patients. Finally, we performed experimental validation at both cellular and patient levels and successfully induced a disulfidptosis phenotype in HCC cells.Discussion: In general, this multifaceted approach provides a comprehensive overview of DRLs profiles in HCC, culminating in the establishment of a novel risk signature that holds promise for predicting prognosis and therapy outcomes of HCC patients.
Background: Hepatocellular carcinoma (HCC) continues to be a major cause of cancer associated deaths worldwide, highlighting the need for new prognostic biomarkers and treatment strategies. Triaptosis, a recently characterized mode of regulated cell death, has shown potential as a therapeutic target in various malignancies, including HCC. Nevertheless, how long non-coding RNAs (lncRNAs) regulate triaptosis, as well as their function in HCC, is still not well understood. Methods: This study integrates bioinformatics and functional validation to delineate the interplay between lncRNAs and triaptosis in HCC progression. Results: Firstly, we confirm that pharmacologically inducing triaptosis, a process centrally mediated by ROS accumulation, with menadione sodium bisulfite (MSB) can inhibit HCC growth both in vitro and in vivo. Furthermore, single-cell RNA sequencing identifies a specific elevation of the triaptosis-related gene MTM1 in malignant hepatocytes. Through systematic bioinformatics analysis of TCGA data, we develop a 5-lncRNA prognostic signature (LINC01134, HPN-AS1, DDX11-AS1, AC009283.1, AC009005.1) with superior predictive power over conventional clinical parameters. Strikingly, functional studies reveal that LINC01134 acts as a crucial oncogenic driver and its depletion suppresses proliferation, migration, and invasion while sensitizing cells to triaptosis via MTM1-mediated PI(3)P catabolism. Conclusions: Collectively, our study confirms that triaptosis is a therapeutically targetable signaling in HCC and proposes LINC01134 as a biomarker and therapeutic target, offering new insights into lncRNA-mediated regulation of cell death for precision oncology.
The precise intraoperative delineation of gastric tumors and their micrometastases remains a major challenge in surgical oncology. To address this, we developed a novel NIR‐II fluorescent probe named SPN01 targeting integrin αvβ3, a receptor upregulated in gastric cancer and associated tumor vasculature. SPN01 was constructed by conjugating RGD peptide to a high‐performance cyanine fluorophore with net neutral charge. In multiple preclinical models, SPN01 enabled high‐contrast visualization of sub‐centimeter orthotopic tumors, detection of occult peritoneal micrometastases as small as 0.5 mm, and specific identification of metastatic lymph nodes. Concurrently, near‐infrared II (NIR‐II, 900–1880 nm) fluorescence guidance facilitated the complete resection of tumors with clear margins, owing to the superior brightness of SPN01 in the NIR‐II window. Notably, ex vivo validation using human gastric cancer specimens confirmed target‐specific binding. Comprehensive pharmacokinetic and safety studies demonstrated rapid dual‐pathway clearance and no obvious toxicity. Following these findings, we conducted a first‐in‐human Phase I clinical trial involving 24 healthy volunteers, which demonstrated a favorable safety profile for SPN01. These findings support SPN01‐assisted NIR‐II fluorescence‐guided surgery as a promising candidate for clinical translation with the potential to enhance the completeness of gastric cancer resection.
Precision surgery in soft tissues is currently hindered by the lack of real-time, depth-resolved visualization. Conventional navigation relies on preoperative images that fail to account for intraoperative deformation, while existing intraoperative tools often lack intuitive spatial correspondence. Here, we propose Surgical Anatomical Structure Transparentization (SAST), an emerging framework anchored by second near-infrared fluorescence imaging. Unlike augmented reality, which merely displays static preoperative models, SAST represents a sensing paradigm that utilizes direct photon scattering suppression to visualize deep anatomy in situ. We delineate the critical technological trajectory—from monocular 2-dimensional fluorescence to 3-dimensional volumetric perception via stereoscopic vision and computational imaging—required to bridge the dimensional gap. By transforming navigation from “referencing a map” to “seeing through tissue”, SAST promises to redefine surgical perception through continuous, real-time anatomical transparency.
Background: Fluorescence-guided surgery (FGS) has emerged as a groundbreaking surgical technique in recent decades. As a real-time, non-invasive, and high-resolution diagnostic technology, FGS provides invaluable assistance to surgeons by offering real-time intraoperative navigation. Research on FGS has evolved substantially over time. Despite extensive research on FGS and its potential clinical applications, there is a notable absence of bibliometric analyses in existing studies. This study aims to fill this gap by mapping the knowledge structure and assessing the evolving trends related to FGS. Materials and methods: This study involved searches conducted on the Web of Science Core Collection database, spanning from 2003 to the end of 2023. To explore emerging trends, we integrated the keyword “NIR-II imaging”. The collected data underwent a comprehensive analysis and visualization based on publications, country of origin, authorship, and keywords. We employed bibliometric software such as VOSviewer, CiteSpace, the R bibliometrix package, and Carrot2 for analysis and visualization purposes. Results: The initial analysis of 1693 articles revealed that the most contributing countries were the USA and China. The most relevant topics encompassed clinical applications such as tumor resection and sentinel lymph node mapping. The most frequently occurring keywords included fluorescent dyes, notably 5-aminolevulinic acid and indocyanine green. Furthermore, statistical analyses of institutions and journals revealed that Leiden University was the leading contributor institution, whereas the Journal of Biomedical Optics was the most published journal. Subsequently, 102 publications specifically addressing NIR-II imaging in FGS were identified and subjected to further analyses. Conclusion: This study offers a comprehensive depiction of FGS. The insights obtained from this analysis hold the potential to inform and guide future research in this field.